March 4, 2025 -- The FDA has approved the first new clot-busting drug in nearly 30 years, offering a faster way to dissolve blood clots in adults who suffer a stroke. The treatment ...

The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

The following is a summary of “Reducing time delays and enhancing reperfusion eligibility related to stroke suspicion by the ...

The ambulance would be the latest addition to Florida’s first mobile stroke treatment unit network, which speeds care to ...

Every year, millions of people die from stroke. In order to win against this disease which occurs the moment when a blood ...

TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...

Stroke is the fifth-leading cause of death nationwide. Brain damage from strokes can be minimized if they are treated ...

As stroke remains one of the leading causes of long-term disability and death worldwide, finding a more efficient and effective treatment is critical for improving patient outcomes and reducing ...

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved TNKase® (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment ...

TNKase is administered as a single intravenous bolus over 5 seconds. The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS ...